ONCO
Onconetix IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
810,040
P/E Ratio
—
EPS
$-82.80
Beta
3.63
52W High
$53.55
52W Low
$1.10
50-Day MA
$4.14
200-Day MA
$12.28
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Onconetix Inc
Onconetix Inc. is a pioneering biotechnology firm dedicated to transforming cancer care through the advancement of innovative diagnostic and therapeutic solutions. Leveraging its proprietary technology platform, the company focuses on enhancing early detection and personalized treatment strategies across various malignancies, thereby addressing a critical need in oncology. With a robust pipeline that reflects its commitment to addressing the growing demand for effective cancer therapies, Onconetix is well-positioned to make a significant impact on patient outcomes through its cutting-edge research and development initiatives in the rapidly evolving landscape of cancer treatment.
Fundamentals
| Revenue (TTM) | 815,370 |
| Gross Profit (TTM) | 632,910 |
| EBITDA | $-6.33M |
| Operating Margin | -422.10% |
| Return on Equity | -115.50% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $4.35 |
| Book Value | $50.53 |
| Price-to-Book | 0.07 |
| Price-to-Sales (TTM) | 0.99 |
| EV/Revenue | 0.307 |
| EV/EBITDA | -0.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -57.40% |
| Shares Outstanding | 692,930 |
| Float | 653,840 |
| % Insiders | 8.79% |
| % Institutions | 2.19% |
Data last updated: 4/9/2026